7-Nitroindazole, or 7-NI, is a heterocyclic small molecule containing an indazole ring that has been nitrated at the 7 position. Nitroindazole acts as a selective inhibitor for neuronal nitric oxide synthase, a hemoprotein enzyme that, in neuronal tissue, converts arginine to citrulline and nitric oxide (NO).[1] Nitric oxide can diffuse through the plasma membrane into neighbouring cells, allowing cell signalling, so nitroindazole indirectly inhibits this signalling process.[2][3][4] Other inhibitors exist such as 3-bromo-7-nitroindazole, which is more potent but less specific,[5] or NPA (N-propyl-L-arginine), which acts on a different site.[6]
Names | |
---|---|
Preferred IUPAC name 7-Nitro-1H-indazole | |
Identifiers | |
3D model (JSmol) | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.019.032 |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C7H5N3O2 | |
Molar mass | 163.1335 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Pharmacology
7-Nitroindazole is under investigation as a possible protective agent against nerve damage caused by excitotoxicity or neurodegenerative diseases.[1][7] It may act by reducing oxidative stress or by decreasing the amount of peroxynitrite formed in these tissues. These effects are related to the inhibition of type 1 nitric oxide synthase. However, anticonvulsive effect is derived from some other mechanisms.[8]
See also
- Dizocilpine (MK-801) a non-competitive antagonist of the NMDA receptor
- Sildenafil a drug for impotence, which inhibits cGMP specific phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP, which is produced by guanylate cyclase, which is activated by nitric oxide produced by eNOS
- tetrahydrobiopterin, cofactor to several enzymes including nitric oxide synthase (NOS)
- protein kinase A (PKA) and protein kinase C (PKC)
References
External links
- 7-nitroindazole at the U.S. National Library of Medicine Medical Subject Headings (MeSH)